Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

AMANTADINE HCL

All products: not a benefit

Other products in the same Health Canada class (N04B) — coverage varies; not interchangeable

  • Bromocriptine (Parlodel): general benefit, Not a benefit
  • Benserazide + levodopa (Prolopa 50-12.5): general benefit
  • Carbidopa + levodopa (Sinemet CR): general benefit, Limited Use, Not a benefit
  • Ropinirole (ReQuip): general benefit, Not a benefit
  • Selegiline (Eldepryl): general benefit, Not a benefit
  • Carbidopa + entacapone + levodopa (Stalevo): limited Use 367

Symmetrel · DIN 01913999 · 10mg/mL · oral liquid

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-11-03 — choose a marketed DIN from the same-category list.Discontinued 2008-11-03 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-11-03 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2008-11-03 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Symmetrel · DIN 01913999 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Health Canada: Cancelled post market since 2008-11-03 · brand SYMMETREL SYRUP 10MG/ML · ATC N04BB01 AMANTADINE, N04BB01 AMANTADINE · form Syrup · route Oral · ingredients AMANTADINE HYDROCHLORIDE 10 MG/ML · company Bristol-myers squibb canada · schedule Prescription
Check this DIN again · Health Canada product record

Symmetrel: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15546 · Verify on the e-Formulary ↗ (DIN 01913999)

Source record
DIN 01913999: Symmetrel Raw flags: notABenefit=Y, sec3=Y Item: 920000032; group id 895; item number 2149; lccId None; manufacturer id BQU Source form: O/L; strength: 10mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01913999 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15546
Interchangeable products
Odan-Amantadine Syrup · DIN 02538601 · $0.0988 PDP-Amantadine Hydrochloride Syrup · DIN 02022826 · $0.0988
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01913999
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2008-11-03 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap

LEVODOPA & CARBIDOPA

· 25 products · Listed, not a benefit (5), Limited Use, codes 64, 65 (2), General benefit (18) · strengths: 100mg & 25mg, 200mg & 50mg, 100mg & 10mg, 250mg & 25mg · CR Tab, Tab

ROPINIROLE

· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 0.25mg, 1mg, 2mg, 5mg · Tab

SELEGILINE HCL

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg · Tab

LEVODOPA & CARBIDOPA & ENTACAPONE

· 5 products · Limited Use, codes 367 · strengths: 75 & 18.75 & 200mg, 125 & 31.25 & 200mg, 50 & 12.5 & 200mg, 100 & 25 & 200mg, 150 & 37.5 & 200mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Antiparkinsonian Treatment pdp-AMANTADINE HYDROCHLORIDE is useful in the treatment of Parkinson's Syndrome and in the short-term management of drug-induced extrapyramidal symptoms. Antiviral Prevention and Treatment  The prevention or chemoprophylaxis of respiratory tract infections caused by Influenza A virus strains, especially in high-risk patients (including those with cardiopulmonary disease, neuromuscular disorders, the elderly, immunocompromised), close household or hospital ward contact of index cases, and those in critical public service positions (e.g. police, firefighters, and medical personnel). In the prophylaxis of influenza early vaccination is the method of choice. When early vaccination is not feasible, or when the vaccine is contraindicated or not available, amantadine hydrochloride may be used for chemoprophylaxis against influenza A virus illness. It is effective against all strains of Influenza A virus which have been tested to date. Because amantadine hydrochloride does not appear to suppress antibody response, it may be given as chemoprophylaxis concurrently with inactivated Influenza A virus vaccine until prot… https://pdf.hres.ca/dpd_pm/00066300.PDF PM date: Jun 13, 2022 Source product: PDP-AMANTADINE HYDROCHLORIDE CAPSULES; DIN 01990403; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Symmetrel: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026